BrightView Holdings shares declined 8.8% in premarket trading following lowered guidance for fiscal 2025. Shares were trading around $15.37. The stock is up 5.4% on the year.

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

CytoSorbents plans to ask Canadian health authorities to reconsider rejecting the company's license application for DrugSorb-ATR, an investigational device designed to reduce the severity of bleeding ...

A Deutsche Bank survey is asking investors what they're looking for on July 9, when a pause on the so-called reciprocal ...

Paramount bought and cancelled about 5.67 million shares under its current buyback program, which authorized it to repurchase up to 7.89 million shares through July 7. The natural gas producer's ...

Portfolio manager Laura Mayfield says some individual investors “are focused on the dividend-yield return, but some might be ...

Software maker Adobe was on the receiving end of a downgrade to sell, with the analyst arguing generative artificial ...

Speaking to Bloomberg TV on the sidelines of a conference hosted by the European Central Bank at Sintra, Taylor said the BOE might decide to change the amount it seeks to cut from the portfolio--a ...

The stock market has seen a historic rally this spring, but not all investors are on board. Ned Davis researchers point the ...

The Cboe Volatility index, or VIX, is below 17 and near its lowest levels since the stock market hit its previous peak in mid February. The VIX is an option-derived measure of expected S&P 500 ...